CO-TREATMENT WITH GROWTH-HORMONE OF SUBOPTIMAL RESPONDERS IN IVF ET

被引：81

作者：

OWEN, EJ

WEST, C

MASON, BA

JACOBS, HS

机构：

[1] Cobbold Laboratories, Middlesex Hospital, London W1N 8AA, Mortimer Street

[2] Hallam Medical Centre, London W1N 5LR

来源：

HUMAN REPRODUCTION | 1991年 / 6卷 / 04期

关键词：

GROWTH HORMONE; PERGONAL; POOR RESPONDERS; IVF ET;

D O I：

10.1093/oxfordjournals.humrep.a137372

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Several growth factors augment the ovarian response to gonadotrophins and growth hormone is known to regulate the production of insulin-like growth factor-1. With this in mind, 20 women who had previously responded sub-optimally to standard ovarian stimulation regimens for in-vitro fertilization and embryo transfer (IVF-ET) were recruited into a randomized trial to study the effect of co-treatment with growth hormone (Norditropin, Novo Nordisk Gentofte A/S). Intramuscular injections of growth hormone (24 IU) or placebo were given on alternate days concurrently with the same daily dosage of gonadotrophin as administered in the patient's pretreatment cycle. Oveerall, there was no improvement in the ovarian response to the growth hormone-augmented regimen of stimulation although there was a tendency for the development of more follicles (P = 0.06). When the results from the patients with ultrasound-diagnosed polycystic ovaries were analysed separately, however, more follicles developed (P = 0.04), more oocytes were collected (P = 0.03) and there was a trend towards higher urinary oestrogen production following growth hormone therapy. There was no improvement in the ovarian response in patients with normal ovaries. The treatment was not associated with any adverse effects. We conclude, therefore, that in a subgroup of patients who respond sub-optimally to standard ovarian stimulation regimens for IVF-ET and who have ultrasound-diagnosed polycystic ovaries, systemic growth hormone is an effective adjunctive therapy.

引用

页码：524 / 528

页数：5

共 22 条

[1]

Adams J., The use of ovarian ultrasound in the selection and monitoring of patients with hypothalamic amenorrhoea, RSM Services, (1986)

[2]

Adashi E.Y., Resnick C.E., D'ercole J., Svoboda M.E., Wyk J.J., Insulin-like growth factors as intraovarian regulators of granulosa cell growth and function, Endocr. Rev, 6, pp. 400-420, (1985)

[3]

Adashi E.Y., Resnick C.E., Svoboda M.E., Wyk J.J., Somatomedin-C synergizes with follicle stimulating hormone in the acquisition of progesterone biosynthetic capacity by cultured rat granulosa cells, Endocrinology, 11, pp. 2125-2142, (1985)

[4]

Adashi E.Y., Resnick C.E., Brodie A.M.H., Svoboda M.E., Wyk J.J., Somatomedin-C mediated potentiation of follicle- stimulation hormone-induced aromatase activity of cultured rat granulosa cells, Endocrinology, 11, pp. 2313-2320, (1985)

[5]

Adashi E.Y., Resnick C.E., Svoboda M.E., Wyk J.J., Somatomedin-C enhances induction of luteinising hormone receptors by follicle stimulating hormone in cultured rat granulosa cells, Endocrinology, 11, pp. 2369-2375, (1985)

[6]

Adashi E.Y., Resnick C.E., Svoboda M.E., Van Wyk J.J., Hascall V.C., Yanagishita M., Independent and synergistic actions of somatomedin-C in the stimulation of proteoglycan biosynthesis by cultured rat granulosa cells, Endocrinology, 11, pp. 456-458, (1986)

[7]

Davoren J.B., Hsueh A.J.W., Li C.H., Somatomedin-C augments FSH-induced differentiation of cultured rat granulosa cells, Am. J. Physiol, 24, pp. E26-E33, (1985)

[8]

Davoren B.J., Hsueh A.J.W., Growth hormone increases ovarian levels of immunoreactive somatomedin C/insulin-like growth factor 1 in vivo, Endocrinology, 11, pp. 888-890, (1986)

[9]

Gardner M.J., Altman D.G., Statistics with Confidence, Tavistock Sq, (1989)

[10]

Homburg R., Eshel A., Abdulla H.L., Jacobs H.S., Growth hormone facilitates ovulation induction by gonadotrophins. Clin, Endocrinol, 29, pp. 113-117, (1988)

← 1 2 3 →